[ad_1]
FILE PHOTO: The Wall Street sign is pictured at the New York Stock exchange (NYSE) in the Manhattan borough of New York City, New York, U.S., March 9, 2020. REUTERS/Carlo Allegri/File Photo
(Reuters) – Wall Street’s main indexes pared gains sharply on Thursday, after a report that Gilead Sciences experimental coronavirus drug flopped in its first randomized clinical trial.
The Chinese trial showed that Gilead’s antiviral, remdesivir, did not improve patients’ condition or reduce the pathogen’s presence in the bloodstream, the Financial Times reported, citing draft documents published accidentally by the World Health Organization.
At 12:51 a.m. ET the Dow Jones Industrial Average was up 68.61 points, or 0.29%, at 23,544.43, the S&P 500 was up 7.46 points, or 0.27%, at 2,806.77 and the Nasdaq Composite was up 33.58 points, or 0.40%, at 8,528.96.
Reporting by Shreyashi Sanyal in Bengaluru; Editing by Anil D’Silva
[ad_2]
Source link